Stockscreener 앱 받기
1.05
1.87%
-0.02
시간 외 거래:
1.06
0.01
+0.95%
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
RAPT scraps zelnecirnon program, stock plunges 46% (update) - MSN
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics stock plunges to 52-week low of $1.11 By Investing.com - Investing.com UK
RAPT Therapeutics announces option repricing to retain talent By Investing.com - Investing.com Nigeria
Leerink Partnrs Issues Optimistic Forecast for RAPT Earnings - MarketBeat
Leerink Partnrs Expects Lower Earnings for RAPT Therapeutics - MarketBeat
RAPT Therapeutics' SWOT analysis: biotech firm faces challenges, seeks new path - Investing.com Canada
RAPT Therapeutics Reports Improved Q3 2024 Results - TipRanks
RAPT Therapeutics' (RAPT) Hold Rating Reaffirmed at Stifel Nicolaus - MarketBeat
Wells Fargo & Company Has Lowered Expectations for RAPT Therapeutics (NASDAQ:RAPT) Stock Price - MarketBeat
RAPT Therapeutics (NASDAQ:RAPT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
RAPT Therapeutics Narrows Q3 Loss by 41%, Cuts R&D Spend Amid Restructuring | RAPT Stock News - StockTitan
RAPT Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Australia
RAPT Therapeutics Inc (RAPT) Quarterly 10-Q Report - Quartzy
RAPT Therapeutics stock hits 52-week low at $1.49 - Investing.com
Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4 - Citeline News & Insights
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Nasdaq Moves Lower; Canaan Shares Surge - Benzinga
JPMorgan cuts Rapt Therapeutics to Underweight By Investing.com - Investing.com UK
JPMorgan Chase & Co. Downgrades RAPT Therapeutics (NASDAQ:RAPT) to Underweight - MarketBeat
U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga
U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga
Rapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines Trials - MarketWatch
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury - The Manila Times
Based on Recent FDA Feedback RAPT Therapeutics Stops - GlobeNewswire
RAPT Therapeutics Halts Key Drug Program After FDA Safety Concerns, Liver Injury | RAPT Stock News - StockTitan
Contrasting RAPT Therapeutics (NASDAQ:RAPT) and Elanco Animal Health (NYSE:ELAN) - Defense World
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth? - Simply Wall St
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN
RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat
RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com
RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com
Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics Inc (RAPT) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Cubist Systematic Strategies LLC Increases Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
XTX Topco Ltd Invests $108,000 in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics' SWOT analysis: biotech stock faces clinical hurdles - Investing.com
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now - Yahoo Finance
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability - Insider Monkey
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers - Insider Monkey
RAPT stock touches 52-week low at $1.76 amid sharp annual decline - Investing.com India
Daily Progress: RAPT Therapeutics Inc (RAPT) Drop -7.25, Closing at 1.79 - The Dwinnex
Federated Hermes Inc. Boosts Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
Acadian Asset Management LLC Raises Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $2.00 by Analysts at UBS Group - Defense World
Market Highlights: RAPT Therapeutics Inc (RAPT) Ends on a High Note at 2.01 - The Dwinnex
RAPT Therapeutics (NASDAQ:RAPT) Given New $2.00 Price Target at UBS Group - MarketBeat
RAPT Therapeutics stock hits 52-week low at $1.82 - Investing.com India
0.93%
3.55%
자본화:
|
볼륨(24시간):